Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 129Recruiting 59Terminated 44Active not recruiting 44Unknown 13Withdrawn 6Not yet recruiting 5Enrolling by invitation 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Genitourinary 3Tumor-Agnostic 2Breast 1

Conditions

Prostatic Neoplasms 3Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × Interventional × enzalutamide × Clear all
NCT03709550 2022-10-05

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Roswell Park Cancer Institute

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT05191017 2022-08-05

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Nuvation Bio Inc.

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02929576 2018-10-22

ENDEAR

Pfizer

Phase 3 Withdrawn
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02380313 2016-10-06

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

GlaxoSmithKline

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT02159690 2015-01-26

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

Johns Hopkins University

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT01663415 2012-09-17

A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Inc

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡